Human clinical-trial data (Phase 1/2 studies in wound healing, cardiac injury, and dry eye) exist only for a different, full-length recombinant thymosin beta-4 product, not for the short synthetic fragment marketed as TB-500, so no completed published human trial has evaluated TB-500 specifically for muscle, tendon, or joint recovery
Dong M, Lu L, Zhang L, Zhang Q, Ungvari GS, Ng CH, et al
What really happens once youve had your glutathione IV drip
MEDI-573 offers a potential targeted treatment strategy for cancer (121)
The synthetic version (BPC-157) is designed to mimic and enhance the regenerative and protective effe